UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000036195
Receipt number R000041200
Scientific Title The Serum CA-125 levels in Atrial Fibrillation
Date of disclosure of the study information 2019/03/14
Last modified on 2019/03/15 20:13:44

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The Serum CA-125 levels in Atrial Fibrillation

Acronym

CA-125 AF

Scientific Title

The Serum CA-125 levels in Atrial Fibrillation

Scientific Title:Acronym

CA-125 AF

Region

Japan


Condition

Condition

Atrial Fibrillation

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigated the relationship the serum CA-125 level and the incidence of atrial fibrillation in the patients aged over 65 years old with peace maker

Basic objectives2

Others

Basic objectives -Others

Analysis of patients' characteristics

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Incidence of Atrial Fibrillation

Key secondary outcomes

1.Exploratory analysis of the patient background
2.The result of the biomaker
3.The ratio of the permanent atrial fibrillation from the paroxysmal atrial fibrillation
4.The incidence of the cardiovascular disease
5.The recurrence of atrial fibrillation after the procedure of pulmonary vein isolation


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

65 years-old <=

Age-upper limit


Not applicable

Gender

Male

Key inclusion criteria

1.The male patients aged over 65 years old at the obtaining informed consent
2.The patients implanted pacemakers over 3 months ago
3.The patients with sinus rhythm at the enrollment
4.The patients implanted atrial pacing lead
5.The patients who have obtained written informed consent after sufficient explanation in advance of participating in this study

Key exclusion criteria

1.Patients presenting shock (systolic blood pressure <90 mmHg)
2.Patients with decompensated heart failure
3.Patients with atrial flutter, atrial tachycardia, permanent atrial fibrillation or long standing atrial fibrillation
4.Patients with bronchiectasis
5.Patients with pancreatic cancer, lung cancer, or colon cancer
6.Patients undergoing chemotherapy or radiation therapy for malignant tumors
7.Patients with severe infections or severe trauma, or within 2 weeks after surgery
8.Patients whose doctors judged them as unsuited to participate in this clinical study

Target sample size

850


Research contact person

Name of lead principal investigator

1st name HARUKI
Middle name
Last name SEKIGUCHI

Organization

National Hospital Organization

Division name

Clinical Research Department

Zip code

245-8575

Address

3-60-2 Harajyuku, Totsuka-ku, Yokohama, Kanagawa

TEL

045-851-2621

Email

sekiguchi.haruki@twmu.ac.jp


Public contact

Name of contact person

1st name Yoshimi
Middle name
Last name Seki

Organization

National Hospital Organization Yokohama Medical Center

Division name

Clinical Research Department

Zip code

245-8575

Address

3-60-2 Harajyuku, Totsuka-ku, Yokohama, Kanagawa

TEL

045-851-2621

Homepage URL


Email

seki.yoshimi.nq@mail.hosp.go.jp


Sponsor or person

Institute

National Hospital Organization

Institute

Department

Personal name



Funding Source

Organization

National Hospital Organization

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Hospital Organization

Address

2-5-21 Higashigaoka, Meguro, Tokyo

Tel

03-5712-5075

Email

700-kenkyu@mail.hosp.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 03 Month 14 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2018 Year 12 Month 18 Day

Date of IRB

2018 Year 12 Month 18 Day

Anticipated trial start date

2019 Year 03 Month 14 Day

Last follow-up date

2022 Year 10 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

None


Management information

Registered date

2019 Year 03 Month 14 Day

Last modified on

2019 Year 03 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041200


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name